Rodríguez de Santiago Enrique, Herreros-de-Tejada Alberto, Albéniz Eduardo, Ramos Zabala Felipe, Fernández-Esparrach Gloria, Nogales Oscar, Rosón Pedro, Peñas García Beatriz, Uchima Hugo, Terán Álvaro, Rodríguez Sánchez Joaquín, de Frutos Diego, Parejo Carbonell Sofía, Santiago José, Díaz Tasende José, Guarner Argente Charly, de María Pallarés Pedro, Amorós Ana, Barranco Daniel, Álvarez de Castro Daniel, Muñoz González Raquel, Marín-Gabriel José Carlos
Servicio de Gastroenterología y Hepatología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, España.
Servicio de Digestivo, Hospital Universitario Puerta de Hierro, Instituto de Investigación Puerta de Hierro-Segovia de Arana (IDIPHISA), Majadahonda, Madrid, España; Hospital La Luz, QuirónSalud, Madrid, España.
Gastroenterol Hepatol. 2024 Feb;47(2):119-129. doi: 10.1016/j.gastrohep.2023.02.008. Epub 2023 Mar 2.
The outcomes of endoscopic submucosal dissection (ESD) in the esophagus have not been assessed in our country. Our primary aim was to analyze the effectiveness and safety of the technique.
Analysis of the prospectively maintained national registry of ESD. We included all superficial esophageal lesions removed by ESD in 17 hospitals (20 endoscopists) between January 2016 and December 2021. Subepithelial lesions were excluded. The primary outcome was curative resection. We conducted a survival analysis and used logistic regression analysis to assess predictors of non-curative resection.
A total of 102 ESD were performed on 96 patients. The technical success rate was 100% and the percentage of en-bloc resection was 98%. The percentage of R0 and curative resection was 77.5% (n=79; 95%CI: 68%-84%) and 63.7% (n=65; 95%CI: 54%-72%), respectively. The most frequent histology was Barrett-related neoplasia (n=55 [53.9%]). The main reason for non-curative resection was deep submucosal invasion (n=25). The centers with a lower volume of ESD obtained worse results in terms of curative resection. The rate of perforation, delayed bleeding and post-procedural stenosis were 5%, 5% and 15.7%, respectively. No patient died or required surgery due to an adverse effect. After a median follow-up of 14months, 20patients (20.8%) underwent surgery and/or chemoradiotherapy, and 9 patients died (mortality 9.4%).
In Spain, esophageal ESD is curative in approximately two out of three patients, with an acceptable risk of adverse events.
我国尚未评估内镜黏膜下剥离术(ESD)治疗食管疾病的疗效。我们的主要目的是分析该技术的有效性和安全性。
对前瞻性维护的全国ESD登记数据库进行分析。纳入2016年1月至2021年12月期间在17家医院(20名内镜医师)通过ESD切除的所有浅表食管病变。排除黏膜下病变。主要结局是根治性切除。我们进行了生存分析,并使用逻辑回归分析评估非根治性切除的预测因素。
共对96例患者进行了102例ESD。技术成功率为100%,整块切除率为98%。R0切除和根治性切除率分别为77.5%(n = 79;95%CI:68%-84%)和63.7%(n = 65;95%CI:54%-72%)。最常见的组织学类型是巴雷特相关肿瘤(n = 55 [53.9%])。非根治性切除的主要原因是黏膜下深层浸润(n = 25)。ESD手术量较少的中心在根治性切除方面效果较差。穿孔率、迟发性出血率和术后狭窄率分别为5%、5%和15.7%。没有患者因不良反应死亡或需要手术治疗。中位随访14个月后,20例患者(20.8%)接受了手术和/或放化疗,9例患者死亡(死亡率9.4%)。
在西班牙,约三分之二的食管ESD患者可实现根治,不良事件风险可接受。